कंपनी का अवलोकन
Elicio Therapeutics, Inc. operates as a clinical-stage biotechnology firm dedicated to the development of immunotherapies specifically designed for cancer treatment. The company focuses its research and development efforts on its lead product candidate, ELI-002, which is a multivalent lymph node-targeted amphiphile peptide vaccine currently undergoing Phase II clinical trials for seven indications including Kirsten rat sarcoma viral sarcoma. This enterprise functions within the broader Healthcare sector, specifically targeting the high-growth and high-risk Biotechnology industry where innovation in oncology plays a pivotal role in therapeutic advancement. The company maintains a relatively small operational scale with a market capitalization of $189.30M and an employee base of 33 individuals, while its annual revenue is currently N/A. The market cap figure of $189.30M indicates that the company is priced based on future potential rather than current earnings, reflecting the typical valuation dynamics of early-stage biotechnology entities that prioritize pipeline development over immediate profitability.
वित्तीय स्वास्थ्य
The company reported net income of $-39,571,000 for the trailing twelve months, with revenue and EBITDA figures also standing at N/A or $-37,510,000 respectively, highlighting a significant gap between top-line activity and bottom-line results that underscores a cost structure heavily weighted toward research and clinical trial expenses. Free cash flow stands at $-21,666,376, which signifies a consumption of cash reserves necessary to fund ongoing clinical operations and drug development phases without generating positive operational liquidity. All three margin metrics—gross margin, operating margin, and profit margin—are recorded at 0.0%, a condition common in biotechnology companies where substantial R&D expenditures often result in negative or negligible margins before commercialization occurs. The balance sheet shows a cash position of $18.56M against total debt of $14.51M, resulting in a debt-to-equity ratio of 887.04, which suggests a highly leveraged financial structure relative to equity but indicates that cash assets currently cover debt obligations. The current ratio is 2.38, indicating that the company holds sufficient liquid assets to cover its short-term liabilities multiple times over, providing a buffer for immediate operational needs. Return on Equity is listed as N/A due to the lack of net income, while Return on Assets stands at -87.2%, revealing that management's utilization of total assets has resulted in a significant loss relative to the asset base employed in the business.
मूल्यांकन आकलन
The trailing P/E ratio is N/A, whereas the forward P/E is -7.35, a discrepancy that implies the market is pricing the stock based on expected future earnings recovery or turnaround rather than historical performance. The price-to-book ratio is 111.85, which indicates that the market is valuing the company at a substantial premium over its book value, a common scenario for biotech firms where intellectual property and pipeline potential are valued higher than tangible assets. The price-to-sales ratio is N/A and the EV/EBITDA stands at -4.94, suggesting that traditional sales-based or earnings-based valuation multiples are not applicable due to the lack of profitable operations and negative earnings. The 52-week high is $14.93 and the 52-week low is $4.60, meaning the current market price sits somewhere within this range, reflecting the high volatility inherent in speculative biotechnology stocks. The beta value is 1.88, which signifies that the stock price is expected to be 88% more volatile than the broader market, indicating higher risk exposure for investors during periods of market fluctuation.
Growth & Income
Revenue growth year-over-year and earnings growth year-over-year are both listed as N/A, preventing a direct comparison of earnings growth relative to revenue expansion at this stage of the company's lifecycle. The company does not pay a dividend, evidenced by a dividend yield of N/A and a payout ratio of 0.0%, meaning the firm reinvests all available capital and retained earnings back into research, development, and clinical trial programs rather than distributing income to shareholders. This non-dividend strategy is consistent with the growth profile of clinical-stage biotechnology companies that prioritize expanding their product pipeline and securing regulatory approvals over providing immediate income returns. Overall, the growth and income profile is characterized by zero current profitability and zero dividend distribution, with the entire financial focus directed toward achieving clinical milestones to potentially generate future commercial revenue.